Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

Home » Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

Abstract

IntroductionIntravenous prostanoid therapy is recommended for severe systemic sclerosis-related digital vasculopathy. The evidence supporting this recommendation is limited.

The aim of this study was to evaluate the safety and efficacy of treating scleroderma spectrum digital vasculopathy with intravenous epoprostenol.

MethodsPatients with a diagnosis of systemic sclerosis who had received intravenous epoprostenol for scleroderma spectrum digital vasculopathy between 1st October 2003 and 1st September 2015 at Boston University Medical Center were identified using ICD-9 code search, and their charts were reviewed in this retrospective case series.

ResultsOf 47 encounters for intravenous epoprostenol infusion for scleroderma spectrum digital vasculopathy, 29 had documentation of improvement as indicated by any of the following: pain relief, increased perfusion of digits as assessed by warmth or color, reduced digital ulcer number or size. In 16 encounters, there was no documentation on whether the indicative condition had improved. No deterioration of the indicative condition was documented in any encounters. Intravenous epoprostenol infusion was well tolerated with few significant adverse effects.

ConclusionsIntravenous epoprostenol infusion in the treatment of scleroderma spectrum digital vasculopathy is safe. The condition improved with intravenous epoprostenol infusion, although there were study design constraints. We describe our protocol for administering intravenous epoprostenol infusion for scleroderma spectrum digital vasculopathy to improve consistency of patient care.

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

Article Subject: Treatment

DOI:10.5301/jsrd.5000255

Authors

Shing T Law, Harrison W Farber, Robert W Simms

Article History

Disclosures

Financial support: No grants or funding have been received for this study.
Conflict of interest: None of the authors has financial interest related to this study to disclose.

This article is available as full text PDF.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under “My PayPerView”. You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Boston University Medical Center, Boston, MA – USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

 

 

 

By | 2017-09-15T11:11:28+00:00 settembre 15th, 2017|JSRD|Commenti disabilitati su Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

About the Author: